Instil Bio, Inc. (TIL)
After hours:
| Previous close | 10.44 |
| Open | 10.28 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 10.17 - 10.37 |
| 52-week range | 6.08 - 14.00 |
| Volume | |
| Avg. volume | 27,022 |
| Market cap | 67.185M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -24.00 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.67 |
ZacksWhat Makes Instil Bio (TIL) a New Buy Stock
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GlobeNewswireInstil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update. Recent Highlights: Announced entering into a strategic collaboration to develop an autologous folate receptor α (FRα)-CoStAR enhanced TIL for a potential investigator-initiated trial (IIT) in non-small cell lung ca
ZacksInstil (TIL) Stock Rises More Than 20% in a Week: Here's Why
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.
